Reviewer’s report

Title: Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne Muscular Dystrophy

Version: 2 Date: 14 October 2008

Reviewer: Andrea Ballabio

Reviewer’s report:

The manuscript entitled "Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne Muscular Dystrophy" by van Vliet et al. correctly demonstrates that multiexon skipping in the dystrophin gene is not feasible as a therapeutic option. There is no possible alternative interpretation of the results. Even using a different experimental system (or cleaner western blot) results cannot change.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests